SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-071899
Filing Date
2023-03-16
Accepted
2023-03-16 06:37:33
Documents
12
Period of Report
2023-03-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d493196d8k.htm   iXBRL 8-K 26241
  Complete submission text file 0001193125-23-071899.txt   145063

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA sage-20230315.xsd EX-101.SCH 2848
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE sage-20230315_lab.xml EX-101.LAB 17236
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sage-20230315_pre.xml EX-101.PRE 10811
6 EXTRACTED XBRL INSTANCE DOCUMENT d493196d8k_htm.xml XML 3291
Mailing Address 215 FIRST STREET CAMBRIDGE MA 02142
Business Address 215 FIRST STREET CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36544 | Film No.: 23737062
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences